Skip to Content

Fluidigm to Announce Q4/Full Year 2013 Financial Results and Host Conference Call for Investors

Jan 31, 2014
Fluidigm to Announce Q4/Full Year 2013 Financial Results and Host Conference Call for Investors
 
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2014 — Fluidigm Corporation (NASDAQ:FLDM) will report its fourth quarter and 2013 full year financial results on February 6, 2014, after close of market.
 
Gajus Worthington, Fluidigm president and chief executive officer, and Vikram Jog, chief financial officer, will host a conference call at 2:00 p.m. PST (5:00 p.m. EST) on February 6, 2014, to discuss fourth quarter and 2013 full year financial results and operating activities. A press release outlining the financial results will be publicly distributed prior to the call.
 
The Fluidigm conference call can be accessed by calling (877) 556-5248Call: (877) 556-5248 (domestic toll-free) or (720) 545-0029Call: (720) 545-0029 (international toll). There will be a Q&A period during the call.
 
Fluidigm will also provide a live stream of its Q4/full year 2013 financial results conference call for investors at: http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PST (4:45 p.m. EST) on February 6, 2014.
 
A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056Call: (855) 859-2056 (domestic toll-free), or (404) 537-3406Call: (404) 537-3406 (international toll), access code 31387666. The conference call will also be archived on the Fluidigm investor’s page at: http://investors.fluidigm.com/.
 
About Fluidigm
 
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets microfluidic systems to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including 18 different commercial integrated fluidic circuits for nucleic acid analysis, and three families of assay chemistries. These systems are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm products are provided: For Research Use Only. Not for use in diagnostic procedures.
 
For more information, please visit www.fluidigm.com.
 
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
 
Contact
 
Michaeline Bunting 
Senior Director, Marketing 
Fluidigm Corporation 
650 737 4190